We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
+9.58%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$441M
AUM Growth
+$117M
Cap. Flow
+$119M
Cap. Flow %
26.99%
Top 10 Hldgs %
89.53%
Holding
21
New
2
Increased
2
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
EFTR
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
+$62.2M
2
JSPR icon
Jasper Therapeutics
JSPR
+$57.5M
3
OKUR
OnKure Therapeutics
OKUR
+$948K
4
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$111K

Top Sells

Rank Stock Value
1
XFOR icon
X4 Pharmaceuticals
XFOR
+$1.49M
2
SIEN
Sientra, Inc.
SIEN
+$280K

Sector Composition

Rank Sector Weight
1 Healthcare 97.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCVX icon
1
Vaxcyte
PCVX
$7.81B
$106M 24%
4,168,718
– –
EFTR
2
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
$67M 15.21%
+192,885
New +$62.2M
JSPR icon
3
Jasper Therapeutics
JSPR
$21M
$58M 13.17%
+562,856
New +$57.5M
VERA icon
4
Vera Therapeutics
VERA
$2.3B
$51.4M 11.66%
2,960,231
– –
PHAT icon
5
Phathom Pharmaceuticals
PHAT
$708M
$38.5M 8.74%
1,203,135
– –
SRRA
6
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$19M 4.32%
876,656
+5,531
+0.6% +$111K
OKUR
7
OnKure Therapeutics
OKUR
$154M
$15.3M 3.47%
207,396
+11,174
+6% +$948K
SIEN
8
DELISTED
Sientra, Inc.
SIEN
$13.5M 3.06%
234,983
-4,101
-2% -$280K
VRNA
9
DELISTED
Verona Pharma
VRNA
$13.4M 3.04%
2,457,499
– –
ACET icon
10
Adicet Bio
ACET
$85.2M
$12.6M 2.87%
100,962
– –
SLNO
11
DELISTED
Soleno Therapeutics
SLNO
$9.5M 2.16%
686,840
– –
NCNA
12
NuCana
NCNA
$5.49M
$8.57M 1.94%
667
– –
XCUR icon
13
Exicure
XCUR
$10.2M
$8.23M 1.87%
46,513
– –
PRTK
14
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$5.06M 1.15%
1,041,131
– –
SYRE icon
15
Spyre Therapeutics
SYRE
$8.54B
$1.91M 0.43%
9,620
– –
MTEM
16
DELISTED
Molecular Templates, Inc.
MTEM
$1.34M 0.3%
13,333
– –
CBAY
17
DELISTED
Cymabay Therapeutics
CBAY
$478K 0.11%
131,036
– –
OBSV
18
DELISTED
ObsEva SA Ordinary Shares
OBSV
$274K 0.06%
87,999
– –
OCGN icon
19
Ocugen
OCGN
$416M
$51K 0.01%
7,111
– –
XFOR icon
20
X4 Pharmaceuticals
XFOR
$375M
– –
-7,663
Closed -$1.49M

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q3 2021 Portfolio in Review

As of Q3 2021, Abingworth held 21 positions worth $441M, up 36% from $324M the previous quarter. Its ten largest holdings account for 90% of the portfolio.

Abingworth deployed $119M of net new capital in Q3 2021, opening 2 new positions and adding to 2 existing holdings. Its largest new stake was eFFECTOR Therapeutics, Inc. Common Stock: 192,885 shares worth $67M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 94% a quarter earlier.

On the sell side, the largest reduction was Sientra, Inc., an estimated $280K trimmed.

  • Abingworth's largest Q3 2021 buy was eFFECTOR Therapeutics, Inc. Common Stock: 192,885 shares worth $67M.
  • Abingworth added most to OnKure Therapeutics in Q3 2021, an estimated $948K increase.
  • Abingworth's biggest Q3 2021 reduction was Sientra, Inc., cutting an estimated $280K.
  • Abingworth fully exited X4 Pharmaceuticals in Q3 2021, selling an estimated $1.49M.
  • Abingworth's ten largest holdings make up 90% of its $441M portfolio in Q3 2021.
  • Abingworth opened 2 new positions and closed 1 in Q3 2021.
  • Abingworth's portfolio value rose 36% quarter-over-quarter to $441M.

Based on Abingworth's 13F filing for Q3 2021, filed 15 Nov 2021.